Labcorp announced today the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical trials where the heart of clinical research is conducted – investigator sites.
Suite of digital and data solutions designed to improve clinical trial efficiency, reduce data delays and simplify investigator site workflows BURLINGTON, N.C. , June 17, 2024 /PRNewswire/ -- LabCorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical trials where the heart of clinical research is conducted – investigator sites. “The patient-investigator-biopharma sponsor relationship is at the foundation of a successful clinical trial. Global Trial Connect simplifies the investigator workflow, improves the patient experience and ultimately enables biopharma sponsors to bring therapies to market faster,” said Jon DiVincenzo, EVP and President, Central Laboratories and International at Labcorp. “As the world’s leading central laboratory, Labcorp is dedicated to improving the pace of clinical trials focusing on the investigator site experience from study initiation to patient recruitment and data collection.” Labcorp Global Trial Connect, available to current Labcorp Central Laboratory clients, incorporates complementary digital and data solutions that help accelerate clinical study startup, maintain study momentum and increase study throughput. Capabilities include:
For more information, visit LabcorpGlobalTrialConnect.com. About Labcorp View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-launches-global-trial-connect-to-accelerate-clinical-trials-302174129.html SOURCE Labcorp | ||
Company Codes: NYSE:LH |